Злокачественные новообразования у больных лимфомой Ходжкина после лучевой терапии по радикальной программе и комбинированной химиолучевой терапии
С. В. Шахтарина, А. А. Даниленко, В. В. Павлов · Клиническая онкогематология. Фундаментальные исследования и клиническая практика · 2008
The data about incidence and types of secondary neoplasms in Hodgkin's disease patients I, II, IIIS, IV (supradiaphragmatic) stages are presented. Between 1968 and 1998, 1789 patients had received radiotherapy (363 pts) or combined radio-chemotherapy (1426 pts) using extended field radiation in total tumor doses 36-40 Gy, and COPP-chemotherapy (cyclophosphamide, vincristine, procarbazine, prednisolonum). The median duration of follow-up was 18 years. Second malignancies were registered in 80 (4,5 %) patients presented with 78 neoplasms (85 of solid type, 1 acute leukemia, 1 non-Hodgkin's lymphoma). Standardized incidence of observed cancers was 459,1 for the entire cohort, 491,1 for female, and 388,7 for male patients, that was superior than expected incidence in Russian population. The relative risks of secondary neoplasms for the entire group was 2,29 (95 percent confidence interval, 1,85 to 2,8); for female patients after radiotherapy only 3,23 (2,11 to 4,75), after combined chemo-radio-therapy 2,08 (1,48 to 2,83); for male patients 2,25 (0,9 to 4,63) and 1,83 (1,04 to 2,96) respectively. Twenty nine of 80 patients (36,2 %) with secondary cancers died. Follow-up care should include careful cancer screening programs.
Cited by 0 works.